Shreefal Mehta

Shreefal Mehta has a mission to transform scientific research into successful commercial products. As the founding CEO of PRC Tech LLC, he has brought high-energy, next-generation supercapacitors for backup power to the market, for diverse applications such as servers, medical devices, board net stabilization, robotics and others.

He is co-founder, Executive Chair and board director of Pulmokine, which is successfully demonstrating a public-private model for bringing innovative much-needed therapies to patients. Previously, he was Vice President of Business and Corporate Development, at Cytopia Inc. It was during his time at Cytopia that Australia’s largest biotech-pharma alliance was announced between Cytopia and Novartis. Cytopia’s lead compound was last purchased by Gilead for $0.5B (from YM Bio).

As a senior executive, Dr Mehta was an invited speaker in international conferences, including the Indian Science Congress and Australian Biotech Summit. He also served for two years as Executive Director of the Radical Innovation program at RPI. In 2006 he received a “40 under 40” business award for rising business leaders in NY.

Dr. Mehta’s research career resulted in over 30 publications in leading science journals, book chapters, and invited talks.